medigraphic.com

2003, Número 1

<< Anterior Siguiente >>

Enf Infec Microbiol 2003; 23 (1)


Esquemas de tratamiento antirretroviral recomendados para pacientes sin tratamiento previo

Idioma: Español
Referencias bibliográficas: 39
Paginas: 5-16
Archivo PDF: 90.24 Kb.


FRAGMENTO

La morbi-mortalidad en los pacientes infectados por el virus de inmunodeficiencia humana se ha modificado dramáticamente con la inclusión de los inhibidores de proteasa (IP) en 1996 y más recientemente con la inclusión de esquemas ahorradores de IP con análogos no nucleósidos inhibidores de la transcriptasa reversa ITRNN (efavirenz y nevirapina), así como combinaciones con tres análogos nucleósidos inhibidores de la transcriptasa reversa ITRAN (AZT, 3TC, ABC). Todas estas combinaciones conforman los esquemas que se denominan “tratamiento antirretroviral altamente activo” (TARAA que es equivalente a sus siglas en inglés HAART) y los cuales tienen un seguimiento protocolizado máximo al momento actual de 5 años.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Benson CA, Deeks SG, Brun SC et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002;185:599-607.

  2. British HIV Association. British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine 2001;10:76-111.

  3. Cameron DW, Japour AJ, Xu Y et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999;13:213-224.

  4. Carpenter CC, Cooper DA, Fischl MA et al. Antiretroviral therapy for HIV infection in adults. JAMA 2000;283:381-390.

  5. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.

  6. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.

  7. Chaisson RE, Keruly JC, Moore RD. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. JAMA 2000;284:3128-3129.

  8. Eron Jr J, Murphy RL, Peterson D et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of Thymidine Analog Regimen Therapy (START II). AIDS 2000;14:1601-1610.

  9. Fletcher CV, Acosta EP, Cheng H et al. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects. AIDS 2000;14:2495-2501.

  10. Flexner C. Dual protease inhibitor therapy in HIV-infected patients. Annu Rev Pharmacol Toxicol 2000;40:649-674.

  11. Glesby MJ, Hoover DR, Vaamonde CM. Osteonecrosis in patients infected with human immunodeficiency virus. J Infect Dis 2001;184:519-523.

  12. Hogg RS, Yip B, Chan KJ et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-2577.

  13. Hogg RS, Heath KV, Yip B et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-454.

  14. Kaplan J, Hanson D, Karon J et al. Late initiation of antiretroviral therapy (at CD4+ lymphocyte count < 200 cells/µL) is associated with increased risk of death. From: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Abstract 520.

  15. Kemper CA, Witt MD, Keiser PH et al. Sequencing of protease inhibitor therapy. AIDS 2001;15:609-615.

  16. Kempf DJ, Rode RA, Xu Y et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998;12:F9-F14.

  17. King M, Bernstein B, Kempf D et al. Comparison of time to achieve HIV RNA < 400 copies/mL and < 50 copies/mL in a phase III, blinded, randomized clinical trial of ABT-378/r vs NFV in ARV-naive patients. From: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Abstract 329.

  18. Knobel H, Guelar A, Valdecillo G et al. Osteopenia in HIV-infected patients. From: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Abstract 629.

  19. Kurowski M, Kaeser B, Mroziekiewicz A et al. The influence of low doses of ritonavir on the pharmacokinetics of nelfinavir 1,250 mg BID. From: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Canada. Abstract 1639.

  20. Li TS, Tubiana R, Katlama C et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-1686.

  21. Lonergan JT, Behling C, Pfander H et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000;31:162-166.

  22. Meyer D, Behrens G, Schneider A et al. Serum lactate in nucleoside analogue treated HIV patients correlates with serum-lipids [abstract]. Antivir Ther 2000;5(Suppl. 5):54. Abstract P52.

  23. Mulligan K, Grunfeld C, Tai VW et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV-1 infection. J Acquir Immune Defic Syndr 2000;23:35-43.

  24. Murphy RL, Brun S, Hicks C et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection. AIDS 2001;15:F1-F9.

  25. Murphy RL, Katlama C, Johnson V et al. The Atlantic study. From: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract LB-22.

  26. Opravil M, Ledergerber B, Furrer H et al. Clinical benefit of early initiation of HAART in patients with asymptomatic HIV infection and CD4 counts > 350/mm3. From: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Abstract LB6.

  27. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.

  28. Phillips AN, Staszewski S, Weber R et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001;286:2560-2567.

  29. Podzamczer D, Ferrer E, Consiglio E et al. Final 12-month results from the COMBINE study. From: 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; July 7-11, 2001; Buenos Aires, Argentina. Abstract 7.

  30. Rizzardi GP, de Boer RJ, Hoover S et al. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. J Clin Invest. 2000;105:777-782.

  31. Robbins G, Shafer R, Smeaton L et al. Antiretroviral strategies in naive HIV+ subjects: comparisons of sequential 3-drug regimens (ACTG 384). Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract LbOr20A.

  32. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-1873.

  33. Staszewski S, Keiser P, Montaner J et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults. JAMA 2001;285:1155-1163.

  34. Staszewski S. Update on study 006-EFV + AZT + 3TC versus the current ‘standard of care’ IDV + AZT + 3TC. Int J Clin Pract Suppl. 1999;103:10-15.

  35. Sterling TR, Chaisson RE, Bartlett JG et al. CD4+ lymphocyte level is better than HIV-1 plasma viral load in determining when to initiate HAART. From: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Abstract 519.

  36. Tebas P, Powderly WG, Claxton S et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14:F63-F67.

  37. US Public Health Service. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Updated February 4, 2002. Disponible en: http://www.hivatis.org/trtgdlns.html#Adult

  38. Yeni PG, Hammer SM, Carpenter CCJ et al. Antiretroviral Treatment for Adult HIV Infection in 2002. Updated Recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-235.

  39. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: Guidelines for a public health approach. Abril 2002.




2020     |     www.medigraphic.com